All In Biotech

Drug Trial Radar · NCT02457598

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

A Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib (ONO/GS-4059) in Combination With Other Targeted Anti-cancer Therapies in Subjects With B-cell Malignancies

Last checked: Nov 20, 2026Latest source record: Jun 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

203

Actual

Start

Jun 16, 2015

Primary completion

Sep 25, 2024

Study completion Sep 25, 2024

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
May 29, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of tirabrutinib (ONO/GS-4059) in combination with other targeted anti-cancer therapies and to evaluate the long-term safety of tirabrutinib as a monotherapy and in combination with other targeted anti-cancer therapies in adults with relapsed or refractory B-cell lymphoproliferative malignancies. This study consists of three parts: Dose Escalation, Dose Expansion, and Long-term Safety Monitoring. During the Dose Escalation phase, participants will be sequentially enrolled in a standard 3 + 3 dose escalation study design, to receive oral tirabrutinib combined with idelalisib entospletinib +/- obinutuzumab. The Dose Expansion Phase will enroll additional participants with a single B-cell lymphoproliferative malignancy disease type to further evaluate efficacy, safety, tolerability, PK, and pharmacodynamics. The Long-term Safety Monitoring phase will evaluate the long-term safety of tirabrutinib both as a monotherapy and in combination with other anti-cancer therapies. As of Amendment 9, all participants currently on the study who have no clinical evidence of disease progression will transition into long-term safety monitoring. Participants from the ongoing Study GS-US-401-1787 and participants who came off Study GS-US-401-1757 and Study GS-US-401-1787 but continued to receive treatment via named patient use (or individual expanded use) will be enrolled into the long-term safety monitoring group (Group VI). Participants enrolled in Group VI will continue the same treatment regimen in Study GS-US-401-1787 or named patient use (or individual expanded use). As of Protocol Amendment 8, the maximum treatment duration for any participant is an additional 6 years from the date of this amendment (ie. until November 2025). As of Amendment 9, entospletinib will be provided until 31 December 2020 to participants who are currently receiving entospletinib. Participants treated with entospletinib as part of a combination regimen with tirabrutinib will stop receiving entospletinib by 31 December 2020 but may continue to be treated with tirabrutinib monotherapy. Idelalisib will be provided as 50 mg tablets until 31 December 2020 and 100 mg tablets until study completion. Participants assigned to the 50 mg tablet will be given the option, at the investigator's discretion, to switch to 100 mg once daily idelalisib dose.

Conditions

  • B-cell Malignancies

Interventions

  • TirabrutinibDrug

    Capsules or tablets administered orally

  • IdelalisibDrug

    Tablets administered orally twice daily

  • EntospletinibDrug

    Tablets administered orally

  • ObinutuzumabDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days
  2. Objective Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) at Week 12 in Participants With Non-Chronic Lymphocytic Leukemia (CLL) Type NHLTime frame: Week 12
  3. ORR: Percentage of Participants With CR or PR in Participants With CLL at Week 24Time frame: Week 24
  4. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Time frame: First dose up to last dose date (up to 441 weeks) plus 30 days

Locations

15 sites in 3 countries. Site status is shown where the registry gives one.

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Indiana University Health Goshen Center for Cancer Care

    Goshen, Indiana

  • Oregon Health and Science University

    Portland, Oregon

  • CHRU de Lille, Hopital Claude Huriez

    Lille, France

  • Hopital Saint Eloi

    Montpellier, France

  • Chu Haut Leveque

    Pessac, France

  • Centre Hospitalier de Lyon Sud

    Pierre-Bénite, France

  • Institut Universitaire du Cancer-Oncopole I.U.C.T-O

    Toulouse, France

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, United Kingdom

  • Cardiff and Vale Health Board, Clinical Research Facility

    Cardiff, United Kingdom

  • Leeds Teaching Hosptials NHS Trust, Dept of Haematology

    Leeds, United Kingdom

  • University Hospitals of Leicester NHS Trust

    Leicester, United Kingdom

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

  • Plymouth Hospitals NHS Trust

    Plymouth, United Kingdom

  • University Hospital Southampton NHS Foundation Trust

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.